Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.77
- Piotroski Score 2.00
- Grade Buy
- Symbol (BDTX)
- Company Black Diamond Therapeutics, Inc.
- Price $2.52
- Changes Percentage (3.72%)
- Change $0.09
- Day Low $2.40
- Day High $2.55
- Year High $7.66
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/11/2025
- Fiscal Year End N/A
- Average Stock Price Target $14.00
- High Stock Price Target $20.00
- Low Stock Price Target $11.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.66
- Trailing P/E Ratio -3.13
- Forward P/E Ratio -3.13
- P/E Growth -3.13
- Net Income $-82,442,000
Income Statement
Quarterly
Annual
Latest News of BDTX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?
While some unprofitable businesses eventually find success, others fail. Black Diamond Therapeutics had a 20-month cash runway in March 2024 with $115m in cash and $68m cash burn. Shareholders should ...
By Yahoo! Finance | 4 months ago -
Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy Right Now?
A list of top biotech penny stocks includes Black Diamond Therapeutics, Inc. (NASDAQ:BDTX). The biotech industry is growing rapidly, with potential for profit despite risks. Black Diamond focuses on t...
By Yahoo! Finance | 4 months ago
